Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer

Biochemical Pharmacology

Volumn 107, Issue , 2016, Pages 29-40

  Zhou, Qin ^a   Ji, Ming ^a   Zhou, Jie ^a   Jin, Jing ^a   Xue, Nina ^a   Chen, Ju ^a   Xu, Bailing ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

BRCA deficient; Breast cancer; DNA damage repair; PARP inhibitor; Zj 6413

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ZJ 6413; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORGANOSILICON DERIVATIVE; PARP1 PROTEIN, HUMAN; PARP2 PROTEIN, HUMAN; QUINAZOLINONE DERIVATIVE; RECOMBINANT PROTEIN; ZJ6413;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG RECEPTOR BINDING; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DRUG AGONISM; DRUG DESIGN; FEMALE; G2 PHASE; HUMANS; MICE, NUDE; ORGANOSILICON COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINONES; RECOMBINANT PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959440170     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.02.015     Document Type: Article

References (46)

1. S.K. Chia, C.H. Speers, Y. D'Yachkova, A. Kang, S. Malfair-Taylor, J. Barnett, and et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 2007 973 979
2. L. Torres, F.R. Ribeiro, N. Pandis, J.A. Andersen, S. Heim, and M.R. Teixeira Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases Breast Cancer Res. Treat. 102 2007 143 155
3. A. Di Leo, G. Curigliano, V. Dieras, L. Malorni, C. Sotiriou, C. Swanton, and et al. New approaches for improving outcomes in breast cancer in Europe Breast 24 2015 321 330
4. J.Y. Wo, A.G. Taghian, P.L. Nguyen, R.A. Raad, M. Sreedhara, J.R. Bellon, and et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy Int. J. Radiat. Oncol. Biol. Phys. 77 2010 188 196
5. A. Paul, and S. Paul The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers Front. Biosci. 19 2014 605 618
6. K.W. Caldecott Protein ADP-ribosylation and the cellular response to DNA strand breaks DNA Repair 19 2014 108 113
7. A. Khanna DNA damage in cancer therapeutics: a boon or a curse? Cancer Res. 75 2015 2133 2138
8. E.S. Tan, K.A. Krukenberg, and T.J. Mitchison Large-scale preparation and characterization of poly(ADP-ribose) and defined length polymers Anal. Biochem. 428 2012 126 136
9. P.S. Kedar, D.F. Stefanick, J.K. Horton, and S.H. Wilson Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts Mol. Cancer Res. 10 2012 360 368
10. M.F. Langelier, A.A. Riccio, and J.M. Pascal PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1 Nucleic Acids Res. 42 2014 7762 7775
11. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, and et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Lancet 376 2010 235 244
12. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, and et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol. 12 2011 852 861
13. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, and et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
14. T. Shimo, J. Kurebayashi, N. Kanomata, T. Yamashita, Y. Kozuka, T. Moriya, and et al. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells Breast Cancer 21 2014 75 85
15. Z. Bao, C. Cao, X. Geng, B. Tian, Y. Wu, C. Zhang, and et al. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis Oncotarget 2015
16. M. Szanto, A. Brunyanszki, J. Marton, G. Vamosi, L. Nagy, T. Fodor, and et al. Deletion of PARP-2 induces hepatic cholesterol accumulation and decrease in HDL levels Biochim. Biophys. Acta 1842 2014 594 602
17. A. Kamboj, P. Lu, M.B. Cossoy, J.L. Stobart, B.A. Dolhun, T.M. Kauppinen, and et al. Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis J. Neuroinflammation 10 2013 49
18. J. Farres, J. Martin-Caballero, C. Martinez, J.J. Lozano, L. Llacuna, C. Ampurdanes, and et al. Parp-2 is required to maintain hematopoiesis following sublethal gamma-irradiation in mice Blood 122 2013 44 54
19. C. Boehler, L. Gauthier, J. Yelamos, A. Noll, V. Schreiber, and F. Dantzer Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells Methods Mol. Biol. 780 2011 313 336
20. N. Xue, J. Jin, D. Liu, R. Yan, S. Zhang, X. Yu, and et al. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways Curr. Cancer Drug Targets 14 2014 671 683
21. Z. Zhu, J. Jin, N. Xue, X. Song, and X. Chen Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors Anal. Biochem. 449 2014 188 194
22. H. Yao, M. Ji, Z. Zhu, J. Zhou, R. Cao, X. Chen, and et al. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors Bioorg. Med. Chem. 23 2015 681 693
23. J. Murai, S.Y. Huang, B.B. Das, A. Renaud, Y. Zhang, J.H. Doroshow, and et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res. 72 2012 5588 5599
24. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
25. Y. He, J.S. Wang, P. Zhang, W.J. Zhang, Q.L. Huang, and Z.C. Hua [Synergistic apoptotic effect of the combination of diosgenin and TRAIL on non-small-cell lung cancer cell line A549 evaluated with the Chou-Talalay method] Yao Xue Xue Bao 48 2013 45 51
26. C. Qi, Q. Zhou, B. Li, Y. Yang, L. Cao, Y. Ye, and et al. Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis Oncotarget 5 2014 9966 9979
27. V. Schreiber, F. Dantzer, J.C. Ame, and G. de Murcia Poly(ADP-ribose): novel functions for an old molecule Nat. Rev. Mol. Cell Biol. 7 2006 517 528
28. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 10 2010 293 301
29. J. Murai, S.Y. Huang, A. Renaud, Y. Zhang, J. Ji, S. Takeda, and et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol. Cancer Ther. 13 2014 433 443
30. Y. Shen, M. Aoyagi-Scharber, and B. Wang Trapping poly(ADP-ribose) polymerase J. Pharmacol. Exp. Ther. 353 2015 446 457
31. S. Postel-Vinay, I. Bajrami, L. Friboulet, R. Elliott, Y. Fontebasso, N. Dorvault, and et al. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer Oncogene 32 2013 5377 5387
32. H. Seimiya Cancer therapy by PARP inhibitors Nihon Rinsho Japanese J. Clin. Med. 73 2015 1330 1335
33. T.A. Hopkins, Y. Shi, L.E. Rodriguez, L.R. Solomon, C.K. Donawho, E.L. DiGiammarino, and et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol. Cancer Res. 13 2015 1465 1477
34. Y. Drew, E.A. Mulligan, W.T. Vong, H.D. Thomas, S. Kahn, S. Kyle, and et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2 J. Natl. Cancer Inst. 103 2011 334 346
35. D.A. Loser, A. Shibata, A.K. Shibata, L.J. Woodbine, P.A. Jeggo, and A.J. Chalmers Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair Mol. Cancer Ther. 9 2010 1775 1787
36. T. Helleday The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings Mol. Oncol. 5 2011 387 393
37. K.J. Dedes, D. Wetterskog, A.M. Mendes-Pereira, R. Natrajan, M.B. Lambros, F.C. Geyer, and et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors Sci. Transl. Med. 2 2010 53ra75
38. P. Baumann, and S.C. West Role of the human RAD51 protein in homologous recombination and double-stranded-break repair Trends Biochem. Sci. 23 1998 247 251
39. H. Tian, Z. Gao, H. Li, B. Zhang, G. Wang, Q. Zhang, and et al. DNA damage response - a double-edged sword in cancer prevention and cancer therapy Cancer Lett. 358 2015 8 16
40. K.K. Khanna, and S.P. Jackson DNA double-strand breaks: signaling, repair and the cancer connection Nat. Genet. 27 2001 247 254
41. M. Patil, N. Pabla, and Z. Dong Checkpoint kinase 1 in DNA damage response and cell cycle regulation Cell. Mol. Life Sci. 70 2013 4009 4021
42. Z. Cai, N.H. Chehab, and N.P. Pavletich Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase Mol. Cell 35 2009 818 829
43. J.W. Janetka, and S. Ashwell Checkpoint kinase inhibitors: a review of the patent literature Expert Opin. Ther. Pat. 19 2009 165 197
44. Q. Cheng, and J. Chen Mechanism of p53 stabilization by ATM after DNA damage Cell Cycle 9 2010 472 478
45. D. Strumberg, A.A. Pilon, M. Smith, R. Hickey, L. Malkas, and Y. Pommier Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff Mol. Cell Biol. 20 2000 3977 3987
46. J. Murai, Y. Zhang, J. Morris, J. Ji, S. Takeda, J.H. Doroshow, and et al. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition J. Pharmacol. Exp. Ther. 349 2014 408 416